FLT3-ITD mutations are detectable in 33% of AMLs, and mutation of the tyrosine kinase domain (TKD) occurs in ~ 10% of AML patients; FLT3 mutations are associated with decreased overall survival and higher rates of relapse and are more common in normal karyotype ones (4, 5). Here, FLT3 is linked to acute myeloid leukemia.